Ketoshot 10

Moderate to severe pain

Oral Adult Moderately Severe Acute Pain Short-term (<5 days) management of moderately severe acute pain that requires analgesia at opioid level; not indicated for minor or chronic painful conditions IV: 30 mg as single dose or 30 mg q6hr; not to exceed 120 mg/day IM: 60 mg as single dose or 30 mg q6hr; not to exceed 120 mg/day PO: 20 mg once after IV or IM therapy, THEN 10 mg q4-6hr; not to exceed 40 mg/day Elderly IV: 15 mg as single dose or 15 mg q6hr; not to exceed 60 mg/day IM: 30 mg as single dose or 15 mg q6hr; not to exceed 60 mg/day PO: 10 mg once after IV or IM therapy, THEN 10 mg q4-6hr; not to exceed 40 mg/day Dosing Considerations Always begin with parenteral therapy; oral administration indicated only as continuation of IV/IM dosing, if necessary Duration of therapy should not exceed 5 days

<2 years Safety and efficacy not established 2-16 years Single dose: 0.5 mg/kg IV/IM once; not to exceed 15 mg Multiple dose: 0.5 mg/kg IV/IM q6hr; not to exceed 5 days

Renal impairment Severe: Contraindicated Moderate (moderately elevated serum creatinine): Use 50% of recommended dosage; not to exceed 60 mg/day IM/IV

Hypersensitivity to aspirin or other NSAIDs, asthma. Hypovolaemia or dehydration. Do not give postoperatively to patients with high risk of haemorrhage. History of peptic ulcer or coagulation disorders. Nasal polyps, angioedema, bronchospasm. Labour. Moderate to severe renal impairment. GI bleeding, cerebrovascular bleeding. As prophylactic analgesic before surgery. Pregnancy, lactation.

Ketorolac inhibits prostaglandin synthesis by decreasing the activity of the cyclooxygenase enzyme.

Elderly, patients weighing <50 kg, hepatic dysfunction, heart failure, predisposition to reduced blood volume or renal blood flow. Mild renal impairment; monitor renal function closely. Lactation: Drug excreted in breast milk with multiple doses; use contraindicated

>10% Headache (17%),Somnolence (3-14%),Dyspepsia (12-13%),GI pain (12-13%),Nausea (12-13%) 1-10% Diarrhea (3-9%),Dizziness (3-9%),Pruritus (3-9%),Edema (1-3%),Increased blood urea nitrogen (BUN) (3%),Constipation (<3%),Purpura (<3%),Increased serum creatinine (2%),Drowsiness (6%),Hypertension (4%) <1% Abnormal thinking,Anaphylaxis,Blurred vision,Bronchospasm,Cholestatic jaundice,Depression,Difficulty in concentration,Dysgeusia,Euphoria,Hemolytic-uremic syndrome,Hepatitis,Hyperkalemia,Hyponatremia,Hypotension,Increased liver function test values,Insomnia,Laryngeal/lingual edema,Liver failure,Melena,Nervousness,Oliguria,Pallor,Peptic ulcer,Rash,Rectal bleeding,Stomatitis,Urinary frequency,Urinary retention,Vasodilation Potentially Fatal: Anaphylaxis. Severe skin reactions. MI, stroke, GI bleeding.

Pregnancy category: C; D in third trimester (may cause premature closure of ductus arteriosus)

May reduce effects of antihypertensives eg ACE inhibitors or angiotensin II receptor antagonists (AIIA). Increased risk of renal toxicity with ACE inhibitors, diuretics. Increased adverse effects with aspirin or other NSAIDs. Hallucinations may occur when used with fluoxetine, thiothixene, alprazolam. Potentially Fatal: Increased risk of GI bleeding with warfarin. May increase toxicity of methotrexate (MTX) and lithium. Increased plasma concentrations with probenecid.